Gain-of-Function Mutations in Acid Stress Response ( evgS ) Protect Escherichia coli from Killing by Gallium Nitrate, an Antimicrobial Candidate-Reference-Cited by-同舟云学术

Gain-of-Function Mutations in Acid Stress Response ( evgS ) Protect Escherichia coli from Killing by Gallium Nitrate, an Antimicrobial Candidate

Published:2021-02-17 Issue:3 Volume:65 Page:
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

Zeng Jie¹,Wu Liwen¹,Liu Zhou²³,Lv Yihua¹,Feng Jinzhi¹,Wang Weijie¹,Xue Yunxin¹,Wang Dai¹,Li Jiabin²,Drlica Karl⁴⁵,Zhao Xilin¹²⁴⁵^ORCID

Affiliation:

1. State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, School of Public Health, Xiamen University, Xiamen, Fujian Province, China

2. Department of Infectious Diseases, The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui Province, China

3. Department of Laboratory Medicine, The Second Hospital of Anhui Medical University, Hefei, Anhui Province, China

4. Public Health Research Institute, New Jersey Medical School, Rutgers University, Newark, New Jersey, USA

5. Department of Microbiology, Biochemistry & Molecular Genetics, New Jersey Medical School, Rutgers University, Newark, New Jersey, USA

Abstract

Widespread antimicrobial resistance encourages repurposing/refining of nonantimicrobial drugs for antimicrobial indications. Gallium nitrate (GaNt), an FDA-approved medication for cancer-related hypercalcemia, recently showed good activity against several clinically significant bacteria.

Funder

National Natural Science Foundation of China

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Link

https://journals.asm.org/doi/pdf/10.1128/AAC.01595-20

Reference47 articles.

1. Bad Bugs, No Drugs: No ESKAPE! An Update from the Infectious Diseases Society of America

2. Progress and Challenges in Implementing the Research on ESKAPE Pathogens

3. Pandrug-resistant Gram-negative bacteria: the dawn of the post-antibiotic era?